• 

  Developing Class C Firmware for Medical Devices

  How to develop Class C Firmware for medical devices and implement Segregation in compliance with the IEC 62304 Standard.

• 

  Using Language Models (AI) In Medical Devices Responsibly

  Risks, potential roles, and tips for using Large Language Models (LLM) or (AI) in medical devices effectively and responsibly. Role of AI in medical devices: In the medical field, generative language models, colloquially known as “AI” or "LLM" must be used responsibly to enhance the skills of clinicians or improve patient experience without exposing either to increased risk.

• 

  Medical Device Design for Testability

  Medical Device Design for Testability during development explores the pros and cons of its application throughout the entire design process design concern throughout the whole design process, ensuring that all parts of the product can be both manipulated and monitored allowing for thorough testing.

• 

  3 “P’s” of Biomedical Product Development Pitfalls

  Three common elements can be observed in biomedical product development projects that are doomed to failure. They are the Three “P’s” – Platform, Point of Care, and Program Manager.

• 

  Similarities and Differences between Medical Device 510(k) and CE Marking

  Understanding similarities and differences between Medical Device 510(k) and CE Marking regulatory pathways helps harmonize overall regulatory strategy.

• 

  ESG Medical Device Impact

  Environmental, Social and Governance (ESG) Medical Device Impact tips to ensure that your products fulfill compliance obligations. Major buyers request ESG reporting from suppliers as new and revised regulations require supply chain attention.

• 

  Gender Equity in Medical Devices: Bridging the Data Gap

  Gender data gap's implications on women's health and strategic measures for its integration into gender gap medical devices, regulatory frameworks and design processes.

• 

  4 Regulatory Trends to Watch In 2024

  Overview of 2024 Regulatory trends include QMSR, LDTs, FDA guidances, and timelines in the EU for MDR and IVDR.

• 

  5 Key Points in FDA’s Real-World Evidence Draft Guidance

  FDA Real-World Evidence Draft Guidance analysis identifies five key points to help understand the potential impact of the draft guidance.

There are no posts to show